



WilBio – Europe

Viral Vectors & Vaccines

May 25–27, 2005

Process Development and Production Issues

Wednesday, May 25

- 7:00–8:00 am: **Registration and Continental Breakfast** — *Exhibit Area Foyer*
- 8:00–8:30 am: **Introduction**
Keith L. Carson — *Conference Chairman*
- 8:30–9:15 am: **Chromatographic Purification of a Recombinant Poliovirus**
Thomas Ouellette — *SAIC-Frederick, Inc.*
- 9:15–10:00 am: **Alternative Influenza Vaccine Production: From Egg-Based to Cell-Based**
Ronald Neeleman, Ph.D. — *Solvay Pharmaceuticals, Inc.*
- 10:00–10:30 am: **Break** — *Exhibit Area*
- 10:30–11:15 am: **Process Development of an Ad35-Based Malaria Candidate Vaccine**
Miranda Weggeman — *Crucell Corporation*
- 11:15–Noon: **Infectivity PCR: A Fast and Sensitive Method to Measure Replication-Competent Adenoviruses**
Marjolijn Schalk, Ph.D. — *RIVM-National Institute of Public Health*
- Noon–1:30 pm: **Lunch** — *Exhibit Area*
- 1:30–2:15 pm: **The EBx Platform: An Embryonic Stem Cell-Derived Substrate for the Industrial Production of Human and Veterinary Viral Vaccines**
Majid Mehtali, Ph.D. — *Vivalis*
- 2:15–3:00 pm: **Large-Scale Production of Clinical Grade Adenoviral Vectors**
Joseph Senesac — *Introgen Therapeutics, Inc.*
- 3:00–3:30 pm: **Break** — *Exhibit Area*
- 3:30–4:15 pm: **Perspectives on the Development of Poxvirus-Based Vaccine Candidates**
Tony D'Amore, Ph.D. — *Aventis Pasteur Ltd.*
- 4:15–5:00 pm: **Current EU Procedures and New Developments**
Martin van der Plas, Ph.D. — *RIVM-National Institute of Public Health*
- 5:00–5:45 pm: **GVAX Prostate Cancer Vaccine–Clinical Development**
Shirley M. Clift — *Cell Genesys, Inc.*
- 6:00–7:30 pm: **Reception** — *Exhibit Area*



Viral Vectors & Vaccines

Thursday, May 26

- 7:30–8:30 am: **American Breakfast — Exhibit Area**
- 8:30–9:15 am: **Development of Anti-HIV Lentiviral Vectors: Results From a Phase I Clinical Trial**
Vladimir Slepushkin, Ph.D. — *VIRxSYS Corporation*
- 9:15–10:00 am: **The Baculovirus-Insect Cell Expression System: Some Nuts and Bolts Resolved**
Monique van Oers, Ph.D. — *Wageningen University*
- 10:00–10:30 am: **Break — Exhibit Area**
- 10:30–11:15 am: **An Overview of the United States Pharmacopeia's Recent Activities in the Areas of Vaccines and Virology**
Tina Morris, Ph.D. — *United States Pharmacopeia*
- 11:15–Noon: **Short Monolithic Columns—Novel Technology for the Separation, Concentration, and Purification of DNA and Viral Particles**
Aleš Štrancar, Ph.D. — *BIA Separations, d.o.o.*
- Noon–6:00 pm: **Free Afternoon with Recommended Activities**
- 6:00–9:00 pm: **Conference Banquet**

Friday, May 27

- 7:30–8:30 am: **Continental Breakfast — Exhibit Area**
- 8:30–10:00 am: **Technical Workshops I**
- 10:00–10:30 am: **Break — Exhibit Area**
- 10:30–Noon: **Technical Workshops II**
- Noon–1:30 pm: **Lunch — Exhibit Area**
- 1:30–2:15 pm: **Q-PCR for Mycoplasma Testing of Biopharmaceutical Products**
Alison Armstrong, Ph.D. — *BioReliance invitrogen bioservices*
- 2:15–3:00 pm: **Cell-Based Protein Vaccine for Influenza: No Eggs and No Live Viruses**
Manon Cox, Drs. — *Protein Sciences Corporation*
- 3:00–3:30 pm: **Break — Exhibit Area (Exhibit & Poster Teardown at 3:30 pm)**
- 3:30–4:15 pm: **Biosafety Issues of Inactivated Polio Vaccine**
Tiny van der Velden, Ph.D. — *Netherlands Vaccine Institute*
- 4:15–5:00 pm: **Optimisation and Scale-Up of Vector Production—Example of AAV Vector**
Otto-Wilhelm Merten, Ph.D.— *Généthon III*

Due to circumstances beyond the control of the conference organizers, the program is subject to change.